Skip to main content


Multimodal Theranostic Nanoplatforms in Cancer Therapy


IGERT trainee, Francisco Reynoso has developed a versatile theranostic nanoplatform. Using magnetic cationic liposomes (MCLs), simultaneous targeting, delivery and in vivo imaging was obtained. Results from this research have shown that these MCLs have potential for improved diagnostics and therapy in cancer treatment.

Address Goals

This research project, supported by National Science Foundation (NSF) through an IGERT grant, utilizes the interesting properties of nanotechnology to address a key challenge in cancer therapy through an interdisciplinary approach. The research team consisted of Francisco Reynoso (IGERT trainee), Prof. Srinivas Sridhar (IGERT Advisor and PI) and Prof. Robert Campbell (IGERT Advisor). This work was done in collaboration with Dr. Mukesh Harsinghani, a leading nanoparticle-based magnetic resonance imaging (MRI) expert at Massachusetts General Hospital. The project is truly interdisciplinary and brings together research scientists from physical sciences, pharmaceutical science and medicine. Working closely with scientist in the forefront of clinical research, it is possible to take fundamental research from the laboratory setting and translate to a clinical setting. This not only enhances the research experience of IGERT trainee but also potential benefit to humankind through this research.